Skip to content

DBD

Diebold Nixdorf, Incorporated

NYSE · USTechnologySoftware - Application
$85.34-0.39%

Price as of Jul 20, 2026

DBD growth

Diebold Nixdorf, Incorporated growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue
+4.3%
EBITDA
-4.3%
EBIT
+60.9%
EPS
+1207.4%
Free cash flow
+46.4%
Operating cash flow
+68.1%

Forward estimates

Revenue
+2.2%
EBITDA
+91.3%
EPS
+109.7%

Three-year CAGR

Revenue
+3.2%
EBITDA
+10.3%
EBIT
+96.2%
Net income
-73.8%
EPS
-65.3%
Free cash flow
+99.8%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.